EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- EOL-1
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- ccle_lineage_sub_subtype
- M5
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.666
- IL6_JAK_STAT3_SIGNALING+0.336
- MYC_TARGETS_V2+0.298
- INTERFERON_GAMMA_RESPONSE+0.256
- INFLAMMATORY_RESPONSE+0.169
- MYC_TARGETS_V1+0.157
- UNFOLDED_PROTEIN_RESPONSE+0.138
- IL2_STAT5_SIGNALING+0.086
- INTERFERON_ALPHA_RESPONSE+0.074
- E2F_TARGETS+0.061
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.740
- PROTEIN_SECRETION-0.723
- TGF_BETA_SIGNALING-0.619
- GLYCOLYSIS-0.518
- CHOLESTEROL_HOMEOSTASIS-0.484
- UV_RESPONSE_DN-0.469
- NOTCH_SIGNALING-0.468
- ANDROGEN_RESPONSE-0.408
- ANGIOGENESIS-0.388
- HEDGEHOG_SIGNALING-0.387
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | KO52_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.932 |
| 2 | HNT34_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.880 |
| 3 | ME1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.878 |
| 4 | BV173_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.872 |
| 5 | OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.859 |
| 6 | OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.858 |
| 7 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.852 |
| 8 | MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.847 |
| 9 | KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.846 |
| 10 | EM2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.666 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.336 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.298 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.256 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.169 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.157 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.138 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.086 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.074 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.061 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.015 | Idelalisib | — uncovered |